179 studies were found. Here are studies 1 to 50.

1.		Recruiting	ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma Conditions: Recurrent Melanoma; stage III melanoma; Stage IV Melanoma
2.		No longer recruiting	ABT-510 in Treating Patients With Locally Recurrent or Metastatic Renal Cell (Kidney) Cancer Conditions: recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
3.		No longer recruiting	ABT-751 in Treating Patients With Locally Recurrent or Metastatic Renal Cell (Kidney) Cancer Conditions: recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
4.		Recruiting	ABT-751 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That is Refractory to Taxane Therapy Conditions: recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
5.		Recruiting	ABX-EGF in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Chemotherapy Conditions: adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent colon cancer; stage IV colon cancer; recurrent rectal cancer; ...
6.		Recruiting	Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma
7.		Recruiting	Adjuvant Oxaliplatin and Capecitabine Compared With Fluorouracil and Leucovorin in Treating Chemotherapy-Naïve (Not Previously Treated) Patients Who Have Undergone Resection for Stage III Colon Cancer Condition: stage III colon cancer
8.		Recruiting	AEE788 in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme Conditions: adult glioblastoma; recurrent adult brain tumor; adult giant cell glioblastoma; adult gliosarcoma
9.		Recruiting	AG-858 and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Were Previously Treated With Imatinib Mesylate Conditions: chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
10.		Recruiting	Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia Condition: Waldenstrom's Macroglobulinemia
11.		No longer recruiting	Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer Conditions: recurrent colon cancer; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer
12.		Recruiting	Anti-Thymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplantation for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; Graft Versus Host Disease; secondary acute myeloid leukemia
13.		Recruiting	APC8015 (Provenge®) in Treating Patients With Asymptomatic Metastatic Androgen-Independent Prostate Cancer Conditions: adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer
14.		Recruiting	APC8015F in Treating Patients With Progressive Metastatic Prostate Cancer and Disease-Related Pain Conditions: adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer
15.		Recruiting	Atrasentan in Treating Patients With Hormone-Naive Prostate Cancer Conditions: recurrent prostate cancer; stage I prostate cancer; stage II prostate cancer; stage III prostate cancer; adenocarcinoma of the prostate
16.		No longer recruiting	Atrasentan in Treating Patients With Prostate Cancer Conditions: adenocarcinoma of the prostate; recurrent prostate cancer; stage II prostate cancer; stage III prostate cancer; stage IV prostate cancer
17.		Recruiting	BAY 43-9006 in Treating Patients With Imatinib Mesylate-Resistant Chronic Phase Chronic Myelogenous Leukemia Conditions: chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia; relapsing chronic myelogenous leukemia
18.		Terminated	BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer
19.		Recruiting	Bendamustine in Treating Patients With Rituximab-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma Conditions: adult non-Hodgkin's lymphoma; indolent or aggressive adult non-Hodgkin's lymphoma
20.		Recruiting	Bevacizumab and Trastuzumab (Herceptin®) in Treating Women With Relapsed or Metastatic Breast Cancer Conditions: recurrent breast cancer; stage IIIC breast cancer; stage IV breast cancer; stage IIIB breast cancer
21.		Recruiting	Bevacizumab in Treating Patients With Metastatic Breast or Colorectal Cancer Who Received Bevacizumab on a Phase II or Phase III Clinical Trial Conditions: stage IV breast cancer; recurrent breast cancer; stage IV colon cancer; Stage IV rectal cancer
22.		Recruiting	Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Kidney Cancer Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma
23.		Completed	Biological Therapy in Treating Patients With Prostate Cancer Conditions: adenocarcinoma of the prostate; recurrent prostate cancer
24.		No longer recruiting	Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Condition: adult non-Hodgkin's lymphoma
25.		No longer recruiting	Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer Conditions: stage III renal cell cancer; Stage IV Renal Cell Cancer; drug extravasation; recurrent renal cell cancer; stage I renal cell cancer; ...
26.		No longer recruiting	BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer Conditions: recurrent breast cancer; stage IV breast cancer
27.		Recruiting	BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate Conditions: chronic phase chronic myelogenous leukemia; relapsing chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
28.		Recruiting	BMS-599626 in Treating Patients With Metastatic Solid Tumors Condition: unspecified adult solid tumor, protocol specific
29.		Recruiting	Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma Conditions: recurrent adult Hodgkin's lymphoma; recurrent adult Burkitt's lymphoma; post-transplant lymphoproliferative disorder; ...
30.		Recruiting	Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma Conditions: grade 1 follicular lymphoma; grade 2 follicular lymphoma; grade 3 follicular lymphoma; marginal zone lymphoma
31.		Recruiting	Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy Condition: recurrent adult diffuse large cell lymphoma
32.		Completed	CC-5013 in Treating Patients With Progressive or Relapsed Metastatic Melanoma Conditions: Recurrent Melanoma; Stage IV Melanoma
33.		Completed	CCI-779 in Treating Patients With Prostate Cancer Condition: stage IV prostate cancer
34.		Recruiting	Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Conditions: recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
35.		Recruiting	Celecoxib in Preventing Lung Cancer in Former Heavy Smokers Conditions: Non-small cell lung cancer; stage I non-small cell lung cancer
36.		No longer recruiting	Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers Condition: Non-small cell lung cancer
37.		No longer recruiting	Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy Conditions: Nose Cancer; Oral Cancer; Throat Cancer
38.		Recruiting	Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery Conditions: localized unresectable adult primary liver cancer; recurrent adult primary liver cancer; adult primary hepatocellular carcinoma
39.		No longer recruiting	Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation Conditions: Waldenstrom's Macroglobulinemia; adult non-Hodgkin's lymphoma
40.		No longer recruiting	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer Conditions: Leukemia; Lymphoma
41.		No longer recruiting	Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer Conditions: recurrent colon cancer; stage IV colon cancer; recurrent rectal cancer; Stage IV rectal cancer
42.		Completed	Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult diffuse small cleaved cell lymphoma; ...
43.		No longer recruiting	Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Conditions: recurrent colon cancer; adenocarcinoma of the rectum; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer; Quality of Life; ...
44.		No longer recruiting	Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Conditions: stage I breast cancer; stage II breast cancer; stage IIIA breast cancer
45.		No longer recruiting	Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy Conditions: Leukemia; Testicular Cancer; ovarian epithelial cancer; Lymphoma; Breast Cancer; Multiple Myeloma; kidney tumor
46.		No longer recruiting	Comparison of Screening Tests in Detecting Cervical Neoplasia Condition: Cervical Cancer
47.		Recruiting	Continued Use of Monoclonal Antibody ABX-EGF in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) Condition: Stage IV Renal Cell Cancer
48.		Recruiting	CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery Conditions: Recurrent Melanoma; stage III melanoma; Stage IV Melanoma
49.		Recruiting	CP-724,714 in Treating Patients With Metastatic Breast Cancer Conditions: recurrent breast cancer; stage IV breast cancer; Male Breast Cancer
50.		Recruiting	CpG 7909 in Treating Patients With Cutaneous T-Cell Lymphoma Conditions: Cutaneous T-Cell Lymphoma; mycosis fungoides and Sezary syndrome